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We have experimentally established appropriate models of atrial ﬁbrillation (AF) with atrial interstitial
ﬁbrosis. Two approaches were adopted. Firstly, left atrial ﬁbrosis was induced by continuous infusion of
angiotensin II (AII). In an electrophysiological study using isolated perfused heart, AF was easily
induced following AII treatment. Repeated whole-body hyperthermia led to the induction of heat-shock
protein 72, which resulted in attenuation of AII-induced left atrial ﬁbrosis and suppression of AF
inducibility. Secondly, atrial ﬁbrosis was induced by pressure overload by abdominal aortic constriction
(AAC). AAC enhanced left atrial expression of monocyte chemoattractant protein-1 and activity of
matrix metalloproteinase-9. Treatment with pioglitazone, a peroxisome proliferator-activated recep-
tor-g agonist, resulted in attenuation of pressure overload-induced left atrial ﬁbrosis and suppression of
AF inducibility. In the same AAC model, the effects of candesartan on gap junction remodeling were
investigated. Connexin 43 (Cx43) of the left atria was ﬁrmly located in the intercalated disks in control
rats. A progressive redistribution of Cx43 from the intercalated disk to the lateral surface (lateraliza-
tion) was observed in AAC rats. Candesartan prevented left Cx43 lateralization. Thus, heat-shock
proteins, pioglitazone, and candesartan could be novel therapeutic approaches to prevent atrial ﬁbrosis
and AF.
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Atrial ﬁbrillation (AF) is the most common type of arrhythmia
observed in a clinical setting, and is associated with signiﬁcant
morbidity and mortality [1,2]. The ‘‘downstream’’ approach that
targets ion channels using antiarrhythmic drugs, has shown to be
limited because antiarrhythmic drugs are ineffective in about halfrt Rhythm Society. Published by E
: þ81 97 586 6059.
hi).of the patients and often induce adverse effects, including proar-
rhythmia [3]. However, the ‘‘upstream’’ approach that targets
processes involved in the development of the substrates that
promote AF, has recently attracted much attention [4]. An atrial
tachypacing-induced AF model has been established to represent
clinical AF,[5] which is characterized by shortening of the atrial
effective refractory period (ERP). Interestingly, Kumagai et al. [6]
reported that in a canine AF model with rapid atrial pacing at
400 beats/min for 5 weeks, rather than shortening the atrial ERP,
extensive interstitial ﬁbrosis was found in the atrial free wall inlsevier B.V. All rights reserved.
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This might be the ﬁrst report to show ‘‘structural remodeling’’ by
atrial tachypacing [6]. However, in patients without structural
heart disease, the atrial tachypacing procedure that is followed in
‘‘normal’’ animals may be applicable only by perpetuation of
paroxysmal AF into permanent AF.
Therefore, we attempted to induce atrial ﬁbrosis with enhanced
AF vulnerability using continuous angiotensin II (AII) infusion [7] or
pressure overload by abdominal aortic constriction (AAC) [8]. These
procedures are more likely to correlate with the mechanisms
underlying newly developed AF in patients with lifestyle diseases,
such as hypertension. Many review articles in terms of upstream
therapies for AF have been published elsewhere [9–11]. Therefore,
in this special review article, we introduce our experimental
approaches for the prevention of atrial ﬁbrosis.2. AF model by continuous infusion of angiotensin II
2.1. Protective effects of heat-shock proteins
The heat-shock proteins (HSPs) are an important family of
endogenous protective proteins that increase in response to a wide
variety of stresses, such as heat shock, hypoxia, hydrogen peroxide,
inﬂammation, and ischemia [12]. We initially showed that oral
geranylgeranylacetone (GGA) is cardioprotective against ischemic
insult via its induction of HSP72 [13]. Mandal et al. [14] showed that
in patients undergoing elective coronary artery bypass surgery, the
preoperative HSP72 content in right atrial tissue obtained at surgery
was higher in patients who did not develop postoperative AF than in
those who did develop AF. Therefore, we tested the hypothesis that
atrial ﬁbrosis and AF evoked by AII could be prevented by the
induction of HSP72 [7]. By using cultured rat left atrial ﬁbroblasts,
we showed that pretreatment with hyperthermia (42 1C for 30 min)
induced HSP72 expression, peaking at 8 h following the application
of hyperthermic conditions (Fig. 1A). In ﬁbroblasts treated under
hyperthermic conditions, AII-induced extracellular signal-regulated
kinase (Erk1/Erk2) phosphorylation (Fig. 1B), a-smooth muscle actin
(a-SMA) expression (Fig. 2), transforming growth factor-b1 (TGF-P-E
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bands of phosphorylated-ERK 1/2 (P-ERK 1/2; top) and total ERK 1/2 (bottom). Below: q
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type-1 and tissue inhibitor of metalloproteinases-1 were attenuated.
A small interfering RNA targeting HSP72 could abolish the anti-
ﬁbrotic effects of hyperthermia (Figs. 1 and 2). Therefore, we
concluded that HSPs, particularly induction of HSP72, have a
dominant role in the suppression of AII-induced ﬁbrotic signal [7].
In addition, in experiments in vivo, repeated hyperthermia (43 1C for
20 min) prevented induction of left atrial interstitial ﬁbrosis by
continuous infusion of AII (Fig. 3). In an electrophysiological study
using isolated perfused heart continuous AII infusion caused slowing
of interatrial conduction without affecting atrial refractoriness. In
AII-treated heart, extrastimuli from the right atrial appendage
resulted in a high incidence of repetitive atrial responses (RARs).
These were suppressed by hyperthermia treatment, resulting in
reduced inducibility of RARs by extrastimuli (Fig. 4) [7]. On the basis
of these observations, we concluded that hyperthermia treatment is
effective in suppressing AII-mediated atrial ﬁbrosis and AF via, at
least in part, induction of HSP72 [7].
On the other hand, several studies indicated that HSP27, a
small-sized HSP, may play a particularly important role in AF
pathogenesis [15,16]. Using HL-1 myocytes derived from mouse
atria, Brundel et al. [15] showed that tachypacing-induced myo-
lysis was prevented by hyperthermia pretreatment or GGA pre-
treatment. They found that HSP27, but not HSP72-transfection,
was sufﬁcient for protection against tachypacing-induced myo-
lysis. Brundel et al. [16] subsequently showed that in HL-1 cells,
tachypacing-induced reduction in duration of L-type Ca2þ current
and action potential was prevented by GGA treatment via induc-
tion of HSP27. They also showed that in dogs in vivo, atrial
tachypacing shortened the atrial ERP, which was attenuated by
administration of GGA. GGA also suppressed tachypacing induced
AF-promoting changes, including AF duration by burst pacing and
AF vulnerability [16]. Although the effects of HSP27 on atrial
ﬁbrosis remain unclear, these observations suggest that HSP
induction particularly that of HSP27, may be an effective
approach to prevent the progression of clinical AF.
Coronary artery disease is associated with an increased risk of AF
[17]. Sinno et al. [18] reported that in dogs, experimental atrial
ischemia resulted in slow conduction, which stabilized the re-RK1
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N. Takahashi et al. / Journal of Arrhythmia 28 (2012) 145–154 147entrant AF circuit. Subsequently, by using the same atrial ischemia
dog model, Sakabe et al. [19] reported that HSP72 induction by
orally administered GGA suppressed conduction heterogeneity and
burst pacing-induced AF duration. In the ischemic and non-ischemic
regions, HSP72 was intensively induced by GGA, whereas HSP27
induction was not signiﬁcant. Studies from our research group
showed that HSP72 induction attenuated ventricular ischemia/
reperfusion injury [13,20–22]. Thus, HSP72 rather than HSP27
appears to have a more important role in the prevention of
ischemia-induced production of AF substrate.
Thus, experimental studies have shown that atrial tachypa-
cing, continuous exposure to AII, or acute atrial ischemia causes
electrical and structural remodeling. This is characterized by
shortening of the atrial ERP and ﬁbrosis-mediated conduction
abnormality, leading to reduction in wavelength, which promotes
AF development (Fig. 5) [23]. Induction of heat shock responses
has been shown to protect the heart against AF by preventing
electrical and structural remodeling. The potent protective role of
heat-shock responses against the progression of clinical AF has
been clariﬁed [24]. Recently, serum HSP27 levels were reportedly
correlated with left atrial dimension, left atrial voltage, and
fractionated intervals, and predicted AF recurrence after catheter
ablation [24]. Baseline serum level of HSP27 also correlated
with interleukin-10 and tumor necrosis factor-a (TNF-a)
levels, which showed that the protective mechanisms of HSP27
against AF could be related to inﬂammation [24]. Taken together,
interventions that induce heat shock responses may prevent
newly developed AF and delay progression of paroxysmal AF to
persistent AF.
The signiﬁcant therapeutic potential of HSP72 for Duchenne
muscular dystrophy (DMD) was recently shown [25]. In mdx and
dko mice, phenocopies of DMD, the function of sarcoplasmic/
endoplasmic reticulum Ca2þ-ATPase (SERCA) showed severe
dysfunctioning. However, BGP-15, a pharmacological inducer of
HSP72, preserved SERCA function and decreased muscle degrada-
tion in association with HSP72 upregulation [25]. The ability ofHSP72 to maintain intracellular Ca2þ homeostasis may prevent
AF, especially where SERCA dysfunction is involved [26].3. AF model by pressure overload (abdominal aortic
constriction)
3.1. Protective effects of pioglitazone against inﬂammatory
proﬁbrotic signals
Pioglitazone, a peroxisome proliferator-activated receptor g
(PPARg) agonist, possesses anti-inﬂammatory properties [27].
Pioglitazone has been shown to attenuate left ventricular hyper-
trophy and ﬁbrosis in salt-sensitive hypertensive rats [28,29].
However, the anti-proﬁbrotic effects of pioglitazone in the atria
have been poorly investigated [30]. We therefore tested the
hypothesis that atrial ﬁbrosis and enhanced vulnerability to AF
evoked by pressure overload could be attenuated by pioglitazone
via suppression of inﬂammatory proﬁbrotic signals [8]. Rats were
subjected to AAC. Pioglitazone (3 mg kg1 day1) or vehicle was
orally administered for 4 weeks. We observed the following. AAC
enhanced the protein expression of monocyte chemoattractant
protein (MCP)-1 (Fig. 6A), TGF-b1 (Fig. 6B), and a-SMA in the left
atrium. Messenger RNA expression of collagen type 1 and atrial
natriuretic peptide in the left atrium was increased by AAC.
Gelatin zymography showed that the activity of promatrix metal-
loproteinase-9 was increased by AAC (Fig. 7). AAC induced left
atrial ﬁbrosis (Fig. 8). In isolated-perfused heart experiments, AAC
did not alter the refractory period of the left atrium or the right
atrium, but it did prolong the inter-atrial conduction time.
Programmed extrastimuli from the right atrium induced AF in
all of the AAC-treated rats. All of these changes induced by AAC
were suppressed by treatment with pioglitazone (Figs. 6–8).
Evidence has shown that inﬂammation contributes greatly to
the progression of atherosclerosis [31]. The process of atrial
structural remodeling observed in AF has been revealed to mimic
that of atherosclerosis [32]. In atherosclerosis, MCP-1 plays an
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Fig. 5. Tachypacing, continuous infusion of angiotensin II (AII), and ischemia induce electrical remodeling and structural remodeling in atria. This results in a reduction in
wavelength, which is a substrate for the development and progression of atrial ﬁbrillation (AF). Induction of heat-shock proteins (HSPs) can prevent atrial remodeling.
(Figure adapted with permission (23)).
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atherosclerotic lesions, and in the formation of intimal hyperpla-
sia after arterial injury [33]. Such early inﬂammatory cell inﬁltra-
tion of injured vessel surface was previously reported to be
suppressed by pioglitazone, in association with the reduction of
activated MCP-1 expression [34]. In a pressure-overloaded ven-
tricle perivascular macrophage inﬁltration, mediated by MCP-1,
provokes interstitial ﬁbrosis via production of inﬂammatory
cytokines, such as TGF-b1. Blocking MCP-1 inhibited TGF-b1
induction [35,36]. Taken together with our observations, [8] it is
conceivable that MCP-1 is a key molecule in AAC-induced
inﬂammatory ﬁbrotic processes in the atria and pioglitazone
attenuates atrial ﬁbrosis, probably via suppression of MCP-1
expression. Yamashita et al. [32] showed that MCP-1 in a left
atrial appendage obtained from patients undergoing cardiac
surgery, was signiﬁcantly higher in patients with AF than in those
with sinus rhythm. Li et al. [37] studied the serum concentrationof MCP-1 in 350 AF patients and 150 control patients and also
reported that serumMCP-1 levels were almost twice as high in AF
patients than in controls.
The anti-AF effects of pioglitazone have been poorly investi-
gated. Shimano et al. [30] reported that pioglitazone reduced the
durations of induced AF, attenuating atrial ﬁbrosis, and reducing
interatrial conduction time, by using rapid ventricular pacing-
induced congestive heart failure (CHF) in rabbits. Their observa-
tions are generally consistent with that of our study [8]. Atrial
proﬁbrotic processes provoked by both CHF and pressure over-
load appeared to share common molecular signatures, at least in
part, and they can be suppressed by pioglitazone. More recently,
Xu et al. [38] showed that pioglitazone prevents age-related atrial
remodeling and AF promotion and that its inhibitory effect is
partially attributable to increases in HSP72 expression and anti-
oxidant activity. Apoptotic cell death and cell survival were also
improved by pioglitazone [38]. These observations suggest that
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ability in AF models by pressure overload, CHF, and aging.
Pioglitazone is expected to be effective at attenuating atrial
ﬁbrosis, possibly via suppression of inﬂammatory proﬁbrotic
processes. Gu et al. [39] conducted a prospective observational
cohort study of 150 consecutive patients undergoing catheter
ablation of drug-refractory paroxysmal AF, who had a history of
type 2 diabetes mellitus. Pioglitazone improved the preservation
of sinus rhythm and reduced the reablation rate [39].
3.2. Protective effects of candesartan against gap junction
remodeling
Experimental studies have shown the beneﬁcial effects of AII
type-1 (AT1) receptor blockers (ARB) in suppression of atrial
ﬁbrosis and AF. For example, treatment with candesartaneffectively suppressed ﬁbrosis and AF in a canine model of AF
with rapid atrial pacing for 5 weeks, in which extensive inter-
stitial ﬁbrosis was found in association with a gradual conduction
prolongation in the atria [6]. In addition to ﬁbrosis, remodeling of
the gap junction due to various etiologies has been recognized in
AF [40]. The predominant gap junction proteins expressed in the
atria are connexins 40 and 43 (Cx40 and Cx43) [41–43]. A
nonsense mutation in Cx40 has been found in patients with
familial AF [41]. In addition, redistribution of Cx43 has been
shown to be involved in abnormal conduction, leading to AF
maintenance [43,44]. We therefore investigated the effects of
candesartan on atrial ﬁbrosis, Cx43 remodeling and enhanced AF
vulnerability induced by pressure overload (unpublished data).
AAC rats were treated with a subdepressor dose of candesartan
(0.1 mg kg1 day1, p.o.) for 4 weeks. The Cx43 of left atrium was
ﬁrmly located in the intercalated disks in the control group, and
N. Takahashi et al. / Journal of Arrhythmia 28 (2012) 145–154 151did not redistribute during the 4-week observation period. Repre-
sentative and quantitative estimation of Cx43 distribution in the
AAC-treated rat left atrium are demonstrated in Fig. 9. Seven days
after the AAC procedure, there was a tendency to redistributeday 7day 0
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N. Takahashi et al. / Journal of Arrhythmia 28 (2012) 145–154152candesartan (Fig. 10). Fig. 11 shows representative histological
sections of left atrium. Compared with the control group
(Fig. 11A), extensive and heterogeneous interstitial ﬁbrosis wasobserved in the AAC-treated group (Fig. 11B). The interstitial
ﬁbrosis induced by AAC was attenuated by candesartan (Fig. 11C).
Fig. 12A and B depict the atrial ERP at 4 basic cycle lengths (BCL)
N. Takahashi et al. / Journal of Arrhythmia 28 (2012) 145–154 153of 200, 150, 120, and 90 ms. In both the right and left atrium no
signiﬁcant differences in ERP were observed among the 3 groups.
Compared with the control group, the AAC-treated group showed
prolonged interatrial conduction time in all BCL tested (Fig. 12C).
This prolongation was inhibited by candesartan treatment. In an
electrophysiological study using isolated perfused heart, AF was
not induced in hearts from the control group. In the AAC-treated
group, S3 extrastimuli induced AF in 9 of 10 rats (90%). In the
AAC-candesartan group, AF induction was observed in only 1 of
10 rats (10%). Treatment with candesartan, therefore, resulted in a
signiﬁcant reduction in the incidence of AF in the AAC-treated
hearts (data not shown).
Redistribution of Cx43 was shown in rats after 24-h of atrial
tachypacing-induced AF [44,45]. The extent of connexin distribu-
tion was shown to correlate with AF duration in goat atrial
tachypacing AF model [46]. The effects of pressure overload on
the cardiac gap junction have been poorly investigated. Emdad
et al. [47] reported that rats developed left ventricular hypertro-
phy, in which Cx43 lateralization was evident at 12 weeks after
abdominal AC. Remodeling of the gap junction in atria by AAC has
not been reported. Rucker-Martin et al. [48] studied Cx43 dis-
tribution in patients with valvular diseases and dilated atria. In
patients characterized by an elevated pulmonary arterial pres-
sure, atrial Cx43 was dephosphorylated and lateralized. Cx43
lateralization extended to a similar degree in patients with sinus
rhythm and AF [48]. Together with our observation that AAC
alone caused Cx43 lateralization, we hypothesize that hemody-
namic pressure overload, without tachypacing, is sufﬁcient to
provide conditions that induce Cx43 remodeling.
Candesartan prevented Cx43 lateralization independent of
blood pressure-lowering and anti-hypertrophic effects. Possible
linkage between AT1 receptor activation and Cx43 expression has
been shown to occur at a cellular level [49]. By using cultured
neonatal rat cardiomyocytes, incubation with AII increased cel-
lular Cx43 expression and its phosphorylation in a concentration-
dependent manner, which was completely inhibited by losartan
[49]. Based on signaling pathway investigations, the authors
concluded that Erk and p38 signaling pathways were involved
in the regulation of Cx43 expression by AII [49]. In addition, cyclic
stretch of cultured neonatal rat cardiomyocytes was shown to
result in increased Cx43 expression and AII release into the
culture media, which was attenuated by losartan [50]. Using
neonatal rat-cultured cardiomyocytes rapid electrical stimulation
of contraction resulted in signiﬁcant upregulation of Cx43 and
increased AII content, in association with an increase in conduc-
tion velocity by extracellular potential mapping using a multiple
electrode array system [51]. These effects induced by rapid
electrical stimulation were prevented by losartan and speciﬁc
inhibitors of Erk and p38 signaling. Therefore, the authors con-
cluded that a short-term rapid electrical stimulation causes Cx43
upregulation and a concomitant increase in conduction velocity,
mainly through activation of Erk and p38 via an autocrine action
of AII [51]. These cellular-level experiments have demonstrated
that stimuli, including AII, mechanical stretch, and rapid electrical
pacing, invariably result in Cx43 upregulation, possibly leading to
an increase in the conduction. It is difﬁcult to applying these
in vitro ﬁndings to experimental in vivo ﬁndings, including that in
our study. In the present study, slowing of interatrial conduction
occurred in association with Cx43 lateralization. Lateralized
connexins have been shown to be nonfunctional, probably leading
to slow conduction [48]. In addition to direct pressure overload by
AAC other mechanisms may contribute to Cx43 lateralization.
Notable interstitial ﬁbrosis may be involved in the processes for
Cx43 lateralization. It has been suggested that interstitial ﬁbrosis
may alter the cyoskeletal network and adhesion proteins that
contribute to the normal organization of connexins [52]. Ourobservations could not clarify whether Cx43 lateralization or
ﬁbrosis has a more dominant role for slowing of interatrial
conduction. Further studies are required to clarify the speciﬁc
role of gap junction remodeling in relation to ﬁbrosis in the
interatrial conduction disturbance induced by pressure overload.
Nevertheless, AT1 receptor blockers, including candesartan, may
be expected to prevent atrial ﬁbrosis, gap junction remodeling
and enhanced AF vulnerability, especially under the pathogenic
condition where the renin-angiotensin system is activated.4. Conclusions
In a clinical setting, the results observed with upstream
therapies appear to be less encouraging. For instance, in GISSI-
AF trial, [53] treatment with valsartan was not associated with a
reduction in the incidence of recurrent AF. This is in contrast to
the results obtained in animal experiments, including our study,
which compellingly shows the protective effect of angiotensin-
converting enzyme inhibitors, ARBs, statins, and n-3 polyunsatu-
rated fatty acids against electrical and structural atrial remodeling
in association with AF [7,8]. One possible explanation is that most
of the clinical studies investigated the recurrence of AF, the
secondary prevention. In patients who have previously developed
AF, atrial structural remodeling may be unexpectedly progressed,
and many mechanisms may be involved. In such conditions, the
above agents will be less likely to prevent the recurrence of AF as
other pathways will still be at play. However, it could be possible
that upstream therapies can reduce new-onset AF. In addition,
upstream therapies may impact mortality and cardiovascular
events in this population. Therefore, sophisticated experimental
studies, possessing signiﬁcant clinical relevance, should be chal-
lengingly continued.Conﬂict of interest
None.
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